To compare the clinicopathological characteristics of patients with stage IB adenocarcinoma (AC) of the cervix and to determine the risk factors for survival and lymph node metastasis. Methods: We retrospectively analyzed 83 patients with stage IB cervical AC treated between 2011 and 2018. The Silva Classification was used to classify all specimens. Kaplan-Meier method was used for survival analysis and Cox regression model used for univariate and multivariate analysis of prognostic factors for survival. A binary logistic regression model was used for the univariate and multivariable analysis of the risk factors for lymph node metastasis. Results: The median follow-up was 45 months (range from 9 to 95 months). A total of 64 (77.12%) patients had stage IB1 and 19 (22.89%) stage IB2. Six patients had recurrence, out of which, 5 died. Univariate analysis revealed that only LVSI (P = 0.001) was a significant prognostic factor. Multivariate analysis showed that LVSI (P = 0.037) was also the only independent significant prognostic factor. By univariate analysis, grade 3 (P = 0.04), LVSI (P < 0.001), depth of stromal invasion ≥10 mm (P = 0.049), Silva C (P < 0.001) were significant risk factors for lymph node metastasis. Multivariate analysis showed that LVSI (P = 0.03) and Silva C (P = 0.023) were the independent risk factors for lymph node metastasis. Conclusions: For stage IB AC, LVSI was the only independent prognostic factor for survival. LVSI and Silva C were the independent risk factors for lymph node metastasis.
Objective: To compare the incidence of ovarian metastasis (OM) in early stage adenocarcinoma (AC) and squamous cell carcinoma (SCC) of the cervix, evaluate the overall survival with ovarian preservation and determine risk factors of OM for early stage AC. Data sources, methods of study selection: We searched the Cochranes database, Embase, and PubMed for publications to November 2020. The articles reporting the incidence, risk factors and overall survival of OM in AC were included. Articles that lacked sufficient data of the odds ratios (ORs) and 95% confidence intervals (CIs) were excluded. A fixed effects model was used to calculate OR and 95% CIs. Eggers test and Funnel plot were used to test the publication bias. Forest plots was used to present and synthesise results. Tabulation, integration and results: In the meta-analysis, the incidence of OM of AC was higher than that of SCC (OR 5.68, 95% CI 4.40-7.32, I 2 = 28.1%) in stage IA-IIB. The incidence of OM was 0% in stage IA, 2.72% in stage IB, 5.95% in stage IIA, and 12.86% in stage IIB AC. Ovarian preservation was not significantly associated with OS (OR 0.53, 95% CI 0.35-0.80, I 2 = 37.8%) in early stage of AC. We found seven risk factors for OM: deep stromal invasion (OR 8.80, 95% CI 3.20-24.23, I 2 = 0%), corpus uteri invasion (OR 6.29, 95% CI 3.36-11.77, I 2 = 21.8%), tumor size >4 cm (OR 3.78, 95% CI 1.86-7.69, I 2 = 30.5%), FIGO stage IIA (OR 3.67, 95% CI 1.98-6.81, I 2 = 0%), FIGO stage IIB (OR 4.31, 95% CI 2.74-6.77, I 2 = 0%), FIGO stage II (OR 3.99, 95% CI 2.49-6.41, I 2 = 0%) and lympho-vascular space invasion (OR 2.90, 95% CI 1.36-6.17, I 2 = 0%). Conclusions: Ovarian preservation is only recommended in stage IA and stage IB AC without risk factors, but not reasonable for stage IIA and IIB AC. Both stage IIA and IIB are risk factors for OM in early stage AC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.